Web Desc
Cancer and Kinases: Lessons from the Clinic
Organizer(s): Brian J. Druker, Charles L. Sawyers and Kenneth W. Bair
Date: February 14 - 19, 2006
Location: Eldorado Hotel & Spa, Santa Fe, NM, USA
Part of the Translational Medicine Series, Sponsored by Pfizer Global Research & Development
For important information on the coronavirus, please click here
Summary of Meeting:
Kinases are one of the most commonly mutated genes in cancer and numerous inhibitors of kinases involved in cancer are being tested in the clinic and many others are in development. Some such as imatinib (Gleevec) have been remarkably successful, while others have been much less successful. In addition, there have been significant improvements in the ability to synthesize specific kinase inhibitors. However, there remains a major need to understand the structural basis of compound selectivity, prospectively identify patients likely to respond to a kinase inhibitor, design improved pharmacodynamic endpoints, and understand the molecular basis of resistance to kinase inhibitor therapy. The goal of this meeting is to review the lessons learned from the successes and failures in the development and clinical application of kinase inhibitors to assist in more effective development and implementation of kinase inhibitors as therapeutic agents.
Scholarship Deadline: October 13 2005
Discounted Abstract Deadline: October 13 2005
Abstract Deadline: November 7 2005
Discounted Registration Deadline: December 14 2005
We gratefully acknowledge additional support for this conference from:
AVEO Pharmaceuticals, Inc.Cell Signaling Technology, Inc.Educational donation provided by AmgenNovartis Institutes for BioMedical ResearchPfizer Global Research & Development
We gratefully acknowledge additional in-kind support for this conference from those foregoing speaker expense reimbursements:

Ambit Biosciences, Inc.

Cell Signaling Technology, Inc.

Chiron Corporation

Exelixis, Inc.

SGX Pharmaceuticals
We gratefully acknowledge the generous grant for this conference provided by:

National Cancer Institute (NCI)
Grant No. 1 R13 CA117397-01
We appreciate the organizations that provide Keystone Symposia with additional support, such as marketing and advertising:

Click here to view more of these organizations
Special thanks to the following for their support of Keystone Symposia initiatives to increase participation at this meeting by scientists from underrepresented backgrounds:

Click here to view more of these organizations

Program

Tuesday, February 14 | 3:00PM - 7:30PM
Registration
Room: Zia Concourse


Tuesday, February 14 | 6:30PM - 7:30PM
Refreshments
Room: Sunset Room


Tuesday, February 14 | 7:30PM - 8:30PM
Keynote Address
Room: Anasazi Ballroom

Speaker 1 of 1
Axel Ullrich, Max Planck Institute of Biochemistry, Germany
From Paul Ehrlich's Dream of a 'Magic Bullet' to Multi-Targeted Cancer Therapy

Wednesday, February 15 | 7:00AM - 8:00AM
Breakfast
Room: Eldorado Court


Wednesday, February 15 | 8:00AM - 11:00AM
Identification of Kinases Targets
Room: Anasazi Ballroom

Speaker 1 of 4
* Michael Stratton, Wellcome Trust Sanger Institute, UK
Sequencing of the Protein Kinase Gene Family in Human Cancers

Wednesday, February 15 | 8:00AM - 11:00AM
Identification of Kinases Targets
Room: Anasazi Ballroom

Speaker 2 of 4
William C. Hahn, Harvard Medical School, USA
Functional Approaches to Identify Kinase Targets in Cancer

Wednesday, February 15 | 8:00AM - 11:00AM
Identification of Kinases Targets
Room: Anasazi Ballroom

Speaker 3 of 4
Roberto D. Polakiewicz, Cell Signaling Technology, Inc., USA
Immunoafinity Profiling of Tyrosine Phosphorylation in Cancer Cells

Wednesday, February 15 | 8:00AM - 11:00AM
Identification of Kinases Targets
Room: Anasazi Ballroom

Speaker 4 of 4
Ronan C. O'Hagan, Merck Research Laboratories, USA
Short Talk: In vivo Genetic Approaches to Identify Mechanisms of Resistance to Inhibition of the HER2 Receptor Tyrosine Kinase

Wednesday, February 15 | 9:20AM - 9:40AM
Coffee Break
Room: Zia Concourse


Wednesday, February 15 | 11:00AM - 1:00PM
Poster Setup
Room: Sunset Room


Wednesday, February 15 | 1:00PM - 10:00PM
Poster Viewing
Room: Sunset Room


Wednesday, February 15 | 4:30PM - 5:00PM
Coffee Available
Room: Zia Concourse


Wednesday, February 15 | 5:00PM - 7:00PM
Structural Chemistry of Kinases and Profiling Kinase Inhibit
ors


Speaker 1 of 5
* Stephen K. Burley, Rutgers University, USA
Fragment Based Drug Discovery for Oncology Targets

Wednesday, February 15 | 5:00PM - 7:00PM
Structural Chemistry of Kinases and Profiling Kinase Inhibit
ors


Speaker 2 of 5
Isabelle S. Lucet, Monash University, Australia
Short Talk: The Structural Basis of Janus Kinase 2 Inhibition by a Potent and Specific Pan-Janus Kinase Inhibitor

Wednesday, February 15 | 5:00PM - 7:00PM
Structural Chemistry of Kinases and Profiling Kinase Inhibit
ors


Speaker 3 of 5
Patrick Zarrinkar, Ambit Biosciences, USA
Understanding the Kinase Inhibitory Profiles of Drugs

Wednesday, February 15 | 5:00PM - 7:00PM
Structural Chemistry of Kinases and Profiling Kinase Inhibit
ors


Speaker 4 of 5
Josephine Atienza, Takeda San Diego, USA
Short Talk: Development, Characterization and Validation of a High Content Label-Free and Real-Time Cell Based Kinase Assay Using a Microelectronic Sensor Array for Screening Selective and Potent Receptor Tyrosine Kinase Inhibitors

Wednesday, February 15 | 5:00PM - 7:00PM
Structural Chemistry of Kinases and Profiling Kinase Inhibit
ors


Speaker 5 of 5
Tony Klink, Wisconsin Crop Improvement Association, USA
Short Talk: Simplifying Kinase Profiling Using ADP Detection Assay with the TranscreenerTM Kinase Assay

Wednesday, February 15 | 7:00PM - 8:00PM
Social Hour with Lite Bites
Room: Eldorado Court/Sunset Room


Wednesday, February 15 | 7:30PM - 10:00PM
Poster Session 1
Room: Sunset Room


Thursday, February 16 | 7:00AM - 8:00AM
Breakfast
Room: Eldorado Court


Thursday, February 16 | 8:00AM - 11:00AM
Example of Imatinib
Room: Anasazi Ballroom

Speaker 1 of 4
* Charles L. Sawyers, Memorial Sloan-Kettering Cancer Center, USA
CML

Thursday, February 16 | 8:00AM - 11:00AM
Example of Imatinib
Room: Anasazi Ballroom

Speaker 2 of 4
Brian J. Skaggs, University of California, Los Angeles, USA
Short Talk: Biological and Biochemical Characterization of Imatinib and Dasatinib-Resistant BCR-ABL Mutants

Thursday, February 16 | 8:00AM - 11:00AM
Example of Imatinib
Room: Anasazi Ballroom

Speaker 3 of 4
Oliver Hantschel, Swiss Federal Institute of Technology Lausanne, Switzerland
Structural and Functional Insights into Bcr-Abl/c-Abl Regulation

Thursday, February 16 | 8:00AM - 11:00AM
Example of Imatinib
Room: Anasazi Ballroom

Speaker 4 of 4
Lukas C. Amler, Genentech, Inc., USA
Short Talk: Epithelial versus Mesenchymal Phenotype Determines in vitro Sensitivity and Predicts Clinical Activity of Erlotinib in Lung Cancer Patients

Thursday, February 16 | 9:20AM - 9:40AM
Coffee Break
Room: Zia Concourse


Thursday, February 16 | 11:00AM - 1:00PM
Poster Setup
Room: Sunset Room


Thursday, February 16 | 1:00PM - 10:00PM
Poster Viewing
Room: Sunset Room


Thursday, February 16 | 4:30PM - 5:00PM
Coffee Available
Room: Zia Concourse


Thursday, February 16 | 5:00PM - 7:00PM
Recent Advancements in the Design of Pharmacodynamic Endpoin
ts

Room: Anasazi Ballroom

Speaker 1 of 3
David Piwnica-Worms, Washington University at St. Louis, USA
Pathway Specific Molecular Imaging Strategies

Thursday, February 16 | 5:00PM - 7:00PM
Recent Advancements in the Design of Pharmacodynamic Endpoin
ts

Room: Anasazi Ballroom

Speaker 2 of 3
* Garry P. Nolan, Stanford University, USA
The Deeper Correlations: Kinases and Metabolism of Single Cells in Complex Populations

Thursday, February 16 | 5:00PM - 7:00PM
Recent Advancements in the Design of Pharmacodynamic Endpoin
ts

Room: Anasazi Ballroom

Speaker 3 of 3
Gary A. Pestano, Ventana Medical Systems, USA
Tissue-Derived Diagnostic Biomarkers in the EGFR Over-Expression Pathway

Thursday, February 16 | 7:00PM - 8:00PM
Social Hour with Lite Bites
Room: Eldorado Court/Sunset Room


Thursday, February 16 | 7:30PM - 10:00PM
Poster Session 2
Room: Sunset Room


Friday, February 17 | 7:00AM - 8:00AM
Breakfast
Room: Eldorado Court


Friday, February 17 | 8:00AM - 11:00AM
EGFR and HER2 Targeted Therapy
Room: Anasazi Ballroom

Speaker 1 of 4
Janet Dancey, National Cancer Institute, National Institutes of Health, USA
EGFR Inhibitors in Clinical Trials

Friday, February 17 | 8:00AM - 11:00AM
EGFR and HER2 Targeted Therapy
Room: Anasazi Ballroom

Speaker 2 of 4
* Daniel A. Haber, Massachusetts General Hospital, USA
EGFR Mutations in Sensitivity and Resistance to Tyrosine Kinase Inhibitors


Friday, February 17 | 8:00AM - 11:00AM
EGFR and HER2 Targeted Therapy
Room: Anasazi Ballroom

Speaker 3 of 4
Dennis J. Slamon, University of California, Los Angeles, USA
Update on HER2 Directed Therapy


Friday, February 17 | 8:00AM - 11:00AM
EGFR and HER2 Targeted Therapy
Room: Anasazi Ballroom

Speaker 4 of 4
Mark X. Sliwkowski, Genentech, Inc., USA
Structure of EGFR Family and Design of New HER-2 Antibodies

Friday, February 17 | 9:20AM - 9:40AM
Coffee Break
Room: Zia Concourse


Friday, February 17 | 4:30PM - 5:00PM
Coffee Available
Room: Zia Concourse


Friday, February 17 | 5:00PM - 7:00PM
Receptor Tyrosine Kinases as Targets
Room: Anasazi Ballroom

Speaker 1 of 5
* Donald Small, Johns Hopkins School of Medicine, USA
Targeting FLT3 for Novel Therapy of Leukemia

Friday, February 17 | 5:00PM - 7:00PM
Receptor Tyrosine Kinases as Targets
Room: Anasazi Ballroom

Speaker 2 of 5
Paolo Michieli, University of Torino Medical School, Italy
Short Talk: Validating the Met tyrosine Kinase as a Target for Anti-Metastatic Therapy

Friday, February 17 | 5:00PM - 7:00PM
Receptor Tyrosine Kinases as Targets
Room: Anasazi Ballroom

Speaker 3 of 5
Ross L. Cagan, Mount Sinai School of Medicine, USA
Short Talk: Drosophila Models for Metastasis and Lead Compound Screening

Friday, February 17 | 5:00PM - 7:00PM
Receptor Tyrosine Kinases as Targets
Room: Anasazi Ballroom

Speaker 4 of 5
Jennifer Cain, Gilead, USA
Short Talk: TEL-PDGFRB-Induced Myeloproliferative Disease in Mice is Sensitive to Stat5a Gene Dosage

Friday, February 17 | 5:00PM - 7:00PM
Receptor Tyrosine Kinases as Targets
Room: Anasazi Ballroom

Speaker 5 of 5
Yana Pikman, Harvard Medical School, USA
Short Talk: A Somatic Activating Mutation in the Thrombopoietin Receptor Leads to Activation of JAK-STAT Signaling in JAK2V617F-Negative Myelofibrosis with Myeloid Metaplasia

Friday, February 17 | 7:00PM - 8:00PM
Social Hour with Lite Bites
Room: Eldorado Court/Sunset Room


Saturday, February 18 | 7:00AM - 8:00AM
Breakfast
Room: Eldorado Court


Saturday, February 18 | 8:00AM - 11:00AM
Intracellular Kinase Targets
Room: Anasazi Ballroom

Speaker 1 of 5
David Solit, Memorial Sloan Kettering Cancer Center, USA
Targeting Oncogenic B-Raf

Saturday, February 18 | 8:00AM - 11:00AM
Intracellular Kinase Targets
Room: Anasazi Ballroom

Speaker 2 of 5
Martin McMahon, University of Utah School of Medicine, USA
Short Talk: A New Mouse Model of BRAFV600E-Induced Tumorigenesis

Saturday, February 18 | 8:00AM - 11:00AM
Intracellular Kinase Targets
Room: Anasazi Ballroom

Speaker 3 of 5
Peter Lamb, Exelixis, USA
High Throughput Discovery of Spectrum-Selective PI3K Pathway Inhibitors

Saturday, February 18 | 8:00AM - 11:00AM
Intracellular Kinase Targets
Room: Anasazi Ballroom

Speaker 4 of 5
* D. Gary Gilliland, Merck & Co., Inc., USA
The Role of JAK2 in Myeloproliferative Disease

Saturday, February 18 | 8:00AM - 11:00AM
Intracellular Kinase Targets
Room: Anasazi Ballroom

Speaker 5 of 5
Helen Piwnica-Worms, Washington University School of Medicine, USA
Cdc25A/Chk1 Regulatory Pathway in Normal and Cancer Cell Cycles

Saturday, February 18 | 9:20AM - 9:40AM
Coffee Break
Room: Zia Concourse


Saturday, February 18 | 4:30PM - 5:00PM
Coffee Available
Room: Zia Concourse


Saturday, February 18 | 5:00PM - 6:30PM
Future of Kinase Targeted Therapies
Room: Anasazi Ballroom

Speaker 1 of 3
Paul Workman, Institute of Cancer Research, UK
Drugging the Cancer Kinome: Optimising Combinatorial Therapeutic Strategies.

Saturday, February 18 | 5:00PM - 6:30PM
Future of Kinase Targeted Therapies
Room: Anasazi Ballroom

Speaker 2 of 3
Dirk Mendel, KAI Pharmaceuticals, Inc., USA
Short Talk: Raf Kinase Inhibitor CHIR-265

Saturday, February 18 | 5:00PM - 6:30PM
Future of Kinase Targeted Therapies
Room: Anasazi Ballroom

Speaker 3 of 3
* Kenneth W. Bair, Athelas Therapeutics, Inc., USA
New Paradigms for Kinase Inhibitor Development

Saturday, February 18 | 6:30PM - 7:30PM
Social Hour with Lite Bites
Room: Eldorado Court/Sunset Room


Saturday, February 18 | 6:30PM - 9:30PM
Entertainment
Room: Eldorado Court/Sunset Room


Saturday, February 18 | 8:00PM - 11:00PM
Cash Bar
Room: Eldorado Court/Sunset Room


Sunday, February 19 | 10:21AM - 10:21AM
Departure


*Session Chair
†Invited, not yet responded.